Regulatory GMP Compliance

Advice about the industry, from industry people.

Trust is your most valuable asset. That’s why our Risk Mitigation and Regulatory Compliance Management team is ready to help you establish trust with regulatory agencies or build it back up again after an issue. Because many of our advisors are former FDA, EMA, and NMPA regulators, we can guide you through sensitive remediation and data integrity audits. And should your biopharmaceutical or medical device operation go global, we can set you up with proactive strategies to build trust along the way.

Additionally, our knowledgeable Agency Readiness Services team helps you submit high-quality dossiers on time and ensures cGMP-compliant facilities are used to gain regulatory success.

Our services include:

  • Auditing: General GxP audits, Good Distribution Practices, quality systems, management controls, FDA-type mock PAIs and inspections, verification audits and effectiveness checks, gap analyses
  • Data Integrity: Directed audits and analysis, subject matter training, procedure development, interviews of staff, internal investigations, fraud evaluation, coordinating efforts with legal counsel
  • Inspection Support: Hosting, front/back room support, mock interviews, readiness assessments, application conformance reviews, review hosting process, site presentations, and tour routes
  • Training: General GxP topics, data integrity, FDA interaction/prep for FDA inspections, and 1:1 mock interviews
  • Technical Writing: SOPs, validation protocols and reports, annual product reviews, FDA correspondence, audit responses, strategic plans, and other technical reports
  • Data Trend Analysis: Collection, review, analysis, and summary reporting
  • Strategic Advisement: Healthcare authority communications/meetings, consent decree remediation and verification activities, warning l/483 responses, preparation for or attendance at FDA meetings

 

Desk-based inspections: A risk-based approach to compliance

Learn more

Is your facility COVID-19 ready?

factsheet thumbnail.JPGWhether you need to remain open during an outbreak, re-open before the outbreak subsides, or simply want to know when it is safe to re-open following the pandemic, Parexel will work with you to determine the right plan for your employee’s and customer’s safety.
 

Download factsheet

The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

Read Now

What’s Around the Corner for FDA Inspections?

Read Now

Demystifying SARS-CoV-2 Testing for COVID-19 (Third Edition – Part 1: Updates and Trends)

Read Now

5 strategies for mitigating the impact of COVID-19 on clinical trials

View Now

An opportunity in a time of crisis: COVID-19 and the new pragmatism

View Now

Parexel's COVID-19 task force

View Now

COVID-19 risks for pediatric patients and implications for clinical trials

View Now

EMA Guidance: Management of Clinical Trials - What it means for Patients?

View Now

FDA Guidance Conduct of Clinical Trials - What it means for Patients?

View Now

COVID-19: Gastrointestinal and hepatic manifestations and implications for clinical trials

View Now

We are always available for a conversation.

*